https://amplyx.com/wp-content/uploads/2019/11/logo.svg00eallisonhttps://amplyx.com/wp-content/uploads/2019/11/logo.svgeallison2018-11-12 16:35:132020-02-26 10:50:30Amplyx Doses First Patient in Phase 2 Trial of APX001 in Patients with Candida Infection
https://amplyx.com/wp-content/uploads/2019/11/logo.svg00eallisonhttps://amplyx.com/wp-content/uploads/2019/11/logo.svgeallison2018-06-07 05:00:222020-02-26 14:18:54Amplyx Announces Presentations on APX001 at American Society for Microbiology Microbe 2018 and the 20th Symposium on Infections in the Immunocompromised Host
https://amplyx.com/wp-content/uploads/2019/11/logo.svg00eallisonhttps://amplyx.com/wp-content/uploads/2019/11/logo.svgeallison2018-06-05 05:12:532020-02-26 14:20:44Amplyx Pharmaceuticals to Participate in BIO International Convention Panel and Present at Jefferies Global Healthcare Conference
https://amplyx.com/wp-content/uploads/2019/11/logo.svg00eallisonhttps://amplyx.com/wp-content/uploads/2019/11/logo.svgeallison2018-04-30 11:33:562020-02-26 14:21:48Amplyx Pharmaceuticals Demonstrates APX001 has Potent Activity Against Deadly Multidrug-Resistant Candida Species
